HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
43 hedge funds and large institutions have $21.5M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
10% more funds holding
Funds holding: 39 → 43 (+4)
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
34% less capital invested
Capital invested by funds: $32.4M → $21.5M (-$10.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$1.11M |
| 2 |
BlackRock
New York
|
+$785K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$562K |
| 4 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$337K |
| 5 |
PCM
Prelude Capital Management
New York
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.41M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$661K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
-$345K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$174K |
| 5 |
Morgan Stanley
New York
|
-$144K |
HTGM Hedge Fund Activity: Q2 2019 in Review
43 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q2 2019, worth a combined $21.5M — down 34% from $32.4M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new HTGM positions and 5 closed out — a net gain of 4 holders — while 10 added to existing stakes and 15 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $1.11M. The largest seller was Fidelity Investments, cutting an estimated $1.41M.
- 43 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q2 2019, up from 39 in Q1 2019.
- Funds reported $21.5M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q2 2019, down 34% quarter-over-quarter.
- 9 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q2 2019 and 5 closed out, a net change of +4 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q2 2019 was Royce & Associates, an estimated $1.11M added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q2 2019 was Fidelity Investments, an estimated $1.41M sold.
Based on aggregated 13F filings for Q2 2019.